Journal: Cytotherapy

Article Title: Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.

doi: 10.1016/j.jcyt.2023.03.006

Figure Lengend Snippet: Fig. 4. aCD38-CAR-NK-92 cells activate against primary MM cells. (A) Frequency of malignant (CD138+) cell content within the BM-derived mononuclear cell samples of three patients with MM. (B) Flow cytometry plots indicating the CD38 expression of the malignant cells. Intensity of CD38 expression (MFI) is depicted within the plots. (C, D) In vitro acti- vation of aCD38-CAR-NK-92 and NK-92-GFP cells after 4-h contact with BM-derived MNC samples from three patients with MM. Results show (C) degranulation and (D) IFNg release. (E) CD38 surface expression of CD138-selected MM cells from two patients as determined by flow cytometry. Intensity of CD38 expression (MFI) is depicted within the plots. (F) Degranulation of aCD38-CAR-NK-92 and NK-92-GFP cells following 4-h co-culture with primary CD138+-selected MM cells of two patients. (G) Combined results of the degranu- lating capacity of aCD38-CAR-NK-92 compared with NK-92-GFP cells after contact with primary CD138+-selected or CD138+-unselected (MNC) MM cell samples.

Article Snippet: Magnetic separation of the malignant CD138+ fraction from the MNC samples was performed using MACSprep Multiple Myeloma CD138 MicroBeads (Miltenyi Biotec, San Diego, CA, USA) where indicated.

Techniques: Derivative Assay, Flow Cytometry, Expressing, In Vitro, Cytometry, Co-Culture Assay